Wu Ke, BravoVax Founder & CEO, said: “As an established human vaccine developer, BravoVax is committed to utilizing its resources and network of connections within the Chinese virology, epidemiology, and regulatory communities to address this new threat to public health. Our physical location in Wuhan, essentially ‘Ground Zero’ for the novel coronavirus outbreak, gives us even greater incentive to be a part of an effective solution. We are excited by the opportunity to partner with GeoVax in leveraging their proven MVA-VLP vaccine platform to address this crisis. We look to collaborate closely with them in moving their vaccine candidate through pre-clinical and clinical testing in the most expeditious way possible in our aim to bring a safe and effective vaccine to those at risk for acquiring this infection.”
News 
Market Data 
Discover 
AI
